Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Pays $1.3M to Buy Out Lease on Unused Facility

NEW YORK, May 23 (GenomeWeb News) - Orchid BioSciences has paid $1.3 million to terminate a lease on a Plainsboro, NJ-based facility that the company had not used for over a year, according to a company filing with the US Securities and Exchange Commission.


Orchid said that it signed a lease on the facility in 1998, but that it has not conducted business there since 2003. A company spokeswoman told GenomeWeb News that the facility housed Orchid's SNP instrumentation and consumables operations, the assets of which were sold to Beckman Coulter in late 2002. 


According to the SEC filing, the property's landlord found a new tenant for the facility, allowing Orchid to buy out of its lease for $100,000 plus one-half of the rent due on the remainder of the lease.


Orchid said that the lease was extinguished on May 18.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.